Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3

In the setting of allogeneic HCT, innate immune activation by LPS potentiates pulmonary GVHD through CXCR3-independent mechanisms. Clinical strategies focused on inhibition of CXCR3 may prove insufficient to ameliorate transplant-related lung disease.